TY - JOUR
T1 - Corrigendum : CD1d-invariant natural killer T cell-based cancer immunotherapy: α-galactosylceramide and beyond (Frontiers in Immunology (2018) 9 (1519) DOI: 10.3389/fimmu.2018.01519)
AU - King, Lisa A.
AU - Lameris, Roeland
AU - de Gruijl, Tanja D.
AU - van der Vliet, Hans J.
PY - 2018
Y1 - 2018
N2 - by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519 In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.
AB - by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519 In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057431281&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30519237
U2 - https://doi.org/10.3389/fimmu.2018.02606
DO - https://doi.org/10.3389/fimmu.2018.02606
M3 - Erratum/Corrigendum
C2 - 30519237
SN - 1664-3224
VL - 9
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - NOV
M1 - 2606
ER -